Skip to content
Chad R. Heatwole, M.D., M.S.

Chad R. Heatwole, M.D., M.S.

Neurology

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Locations

Neurology

601 Elmwood Avenue, 1st Floor
Rochester, NY 14642

About Me

Chad Heatwole, MD, MS-CI is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center. He has an engineering degree from Virginia Tech, a medical degree from the Medical College of Virginia, a master's degree in clinical investiga...
Chad Heatwole, MD, MS-CI is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center. He has an engineering degree from Virginia Tech, a medical degree from the Medical College of Virginia, a master's degree in clinical investigation, and he has completed a University of Rochester neurology residency, electrophysiology fellowship, and NIH-funded neuromuscular experimental therapeutics fellowship. He has had continuous grant funding over the last 17 years and has served as the Principal Investigator on dozens of research grants, including awards from the National Institutes of Health (NIH), Muscular Dystrophy Foundation, New York State, and numerous research foundations. Dr. Heatwole's research has led to the development of an internationally recognized network dedicated to improving the quality-of-life of patients with neuromuscular diseases through patient-centered clinical research, therapeutic development, and the discovery of a novel therapeutic approach for patients with muscular dystrophy. His professional interests include providing optimal care to patients with neuromuscular disorders, conducting electrodiagnostic studies, training medical personnel, developing novel experimental therapeutics for neurological diseases though clinical trials, and developing and validating disease-specific, patient-relevant endpoint measures for use in clinical trials and patient monitoring.

Professional Background

Dr. Heatwole is Director of the Center for Health and Technology at the University of Rochester Medical Center. The Center for Health and Technology is a world-renowned academic research organization that specializes in the conduct, planning, management, implementation, and analysis of large multi-c...
Dr. Heatwole is Director of the Center for Health and Technology at the University of Rochester Medical Center. The Center for Health and Technology is a world-renowned academic research organization that specializes in the conduct, planning, management, implementation, and analysis of large multi-center clinical research studies. Through his role as Director, Dr. Heatwole guides an international multi-faceted research and operations center dedicated to harnessing state-of-the-art technologies and advancing human therapeutics, research, health, and clinical care.

Dr. Heatwole is board certified in both neurology and neuromuscular disease with sub-specialty fellowship training in neuromuscular medicine, electrophysiology, and experimental therapeutics. Dr. Heatwole is committed to: 1) providing quality care to patients with neurological and neuromuscular disease; 2) teaching students, residents, and fellows; and, 3) training faculty in therapeutics and outcome measure development research. His main clinical focus is in the management and diagnosis of patients with neuromuscular disease. Working in a well-established neuromuscular disease clinic at URMC, Dr. Heatwole’s "myotonia clinic" forms a key resource for international patient recruitment and therapeutic care at the University of Rochester. Through this clinic, he provides clinical care and research opportunities to children and adults with dystrophic and non-dystrophic myotonic disorders, as well as a diverse group of neuromuscular patients with both rare and common disorders.

Certified Specialties

Neurology - American Board of Psychiatry & Neurology

Neuromuscular Medicine - American Board of Psychiatry & Neurology

Faculty Appointments

Professor - Department of Neurology, Center for Health and Technology (SMD)

Director - Center for Health and Technology

Credentials

Residency & Fellowship

Fellowship, Clinical Neurophysiology, University of Rochester Medical Center. 2005 - 2006

Residency, Neurology, University of Rochester Medical Center. 2002 - 2005

Internship, University of Rochester Medical Center. 2001 - 2002

Education

MD | Virginia Commonwealth University Medical School. 2001

Awards

University of Rochester Master Mentors Program.. 2016

Myotonic Dystrophy Foundation (MDF) Travel Award to Facilitate Myotonic Dystrophy Health Index (MDHI) Translational Research. 2015

Chairman of Patient Reported Outcome Measures for Myotonic Dystrophy; OMMYD Meeting. 2013

Chairman of DM1 Clinical Trials & Biomarkers Session. IDMC-. 2013

Chairman of Ethical-Legal-Social Issues in Myotonic Dystrophy Session. IDMC-9. 2013

Myotonic Dystrophy Foundation Research Grant (Supervising Mentor for Dr. Nick Johnson). 2012 - 2014

FDA Research Grant: Mexiletine Treatment in Myotonic Dystrophy Type-1 (Co-Investigator). 2011 - 2015

Clinical Research Loan Repayment Grant Renewal Recipient. 2010

NIH Clinical Research Loan REpayment Grant REnewal Recipient. 2010 - 2012

NIH Clinical Research Loan Repayment Grant Recipient. 2008 - 2010

Clinical Research Loan Repayment Grant Renewal Recipient. 2008

Paul Wellstone Muscular Dystrophy Cooperative Research Center Umbrella Center. 2008

2008 Muscular Dystrophy Association Translational Research Infrastructure Grant Award Winner (Funding from 2008-2011). 2008 - 2011

ECRIP (Empire Clinical Research Investigator Program) Grant Award Winner (. 2008 - 2010

NIH K23 Career Development Grant Award Winner (NIAMS). 2008 - 2013

NIH Clinical and Translational Science Institute K12 Award Recipient. 2007

NIH Clinical Research Loan Repayment Grant Recipient. 2006 - 2008

NIH Experimental Therapeutics Grant Recipient for. 2006 - 2007

Ad Hoc editor for Neurology. 2005

American Neurology Association Scholarship Winner, Toronto 2004. 2004

UCB Pharma, Inc. Neurology Resident Scholar. 2003

UCB Pharma, Inc. Neurology Resident Scholar. 2003. 2003

Student Elective Term Scholarship Winner (MMA) 1999. 1999

S.O.M. State Discretionary Scholarship Winner. 1998 - 1999

S.O.M. State Discretionary Scholarship Winner 1998, 1999. 1998 - 1999

Awarded Virginia Tech's Best ESM 1997 Ind. Senior Project Presentation. 1997

Student Elective Term Scholarship Winner (MMA) 1999.

Awarded Virginia Tech's Best ESM Ind. Senior Project Presentation 1997.

Tau Beta Pi National Engineering Honor Society.

Golden Key Member.

Dean's List (General Engineering, and in ESM).

Board of Supervisors Academic Excellence Award.

American Neurology Association Scholarship Winner 2004.

Tau Beta Pi National Engineering Honor Society.

Golden Key Member.

Dean's List (General Engineering, and in ESM).

Board of Supervisors Academic Excellence Award.

Patient and Family-Centered Care award (2011).

Patient and Family Centered Care Award.

Strong Star Award for Exceptional Service and Displaying Compassion and Respect to Patients, Families and Co-workers.

Recognized by 2019 medical student survey as one of the University of Rochester's Inspiring Faculty Members.

Muscle and Nerve award for authorship of one of the most read/viewed manuscripts in 2018-2019.

Research

Dr. Heatwole’s research laboratory is internationally known for therapeutics research and the development, validation, and analysis of highly sensitive patient-relevant outcome measures for use in drug labeling trials. Dr. Heatwole has designed and implemented numerous investigator-initiated clinica...
Dr. Heatwole’s research laboratory is internationally known for therapeutics research and the development, validation, and analysis of highly sensitive patient-relevant outcome measures for use in drug labeling trials. Dr. Heatwole has designed and implemented numerous investigator-initiated clinical studies and has developed more than 100 disease-specific instruments. These instruments are extensively used globally to measure therapeutic gain during clinical trials and have been used in academic initiated trials, pharmaceutic sponsored trials, government initiated trials, and as clinical markers of disease burden. Through his joint role as Director of the Center for Health and Technology and Director/Founder of the Outcomes Division at the Center for Health and Technology, Dr. Heatwole facilitates the study, development, evaluation, and approval of promising human therapeutics. Diseases that he is currently focusing on include:

Myotonic dystrophy type-1 (DM1)
Myotonic dystrophy type-2 (DM2)
Congenital myotonic dystrophy (CMD)
Juvenile myotonic dystrophy (JMD)
Charcot-Marie Tooth (CMT)
Inclusion body myositis (IBM)
Facioscapulohumeral muscular dystrophy (FSHD)
Spinal muscular atrophy (SMA)
Huntington’s disease (HD)
Amyotrophic lateral sclerosis (ALS)
Friedreich’s ataxia (FA)
Duchenne muscular dystrophy (DMD)
Cerebral cavernous malformation (CCM)
Traumatic Brain Injury (TBI)
Crohn’s disease (CD)
Lung cancer (LC)
Parkinson’s Disease (PD)
Alzheimer’s Disease (AD)
Limb Girdle Muscular Dystrophy (LGMD)
Dystonia (DYS)
Mitochondrial Disease (MD)
Cardiomyopathy (CM)
Adrenomyeloneuropathy (AMN)
Adrenoleukodystrophy (ALD)
Spinal-bulbar muscular atrophy (SBMA)

Dr. Heatwole is fully committed to the study and development of novel experimental therapeutics. He has planned, conducted, and analyzed numerous clinical studies including ones involving mexiletine, recombinant human insulin-like growth factor, antisense oligonucleotides, and novel endocrine based approaches.

Dr. Heatwole’s other research initiatives seek to better understand the baseline abnormalities associated with neuromuscular disease, understand the association between biomarkers and disease severity, and predict how muscular dystrophies progress over time. This work has led to the identification of defining laboratory characteristics in muscular dystrophies, data on the disease progression in FSHD and myotonic dystrophy, outcome measure development, biomarker discovery, evidence-based guidelines, and a novel differentiating clinical sign for myotonic dystrophy type-1 and type-2.

Research Lab

Center for Health + Technology

Visit Lab Website

Patents

The FSHD-Health Index

Issue date: May 08, 2013

Patent #: TXu 1-867-274

Country: United States

Inventors: Chad R Heatwole

The Myotonic Dystrophy Health Index (MDHI)

Issue date: March 26, 2013

Patent #: TXu 1-859-815

Country: United States

Inventors: Chad R Heatwole

Congenital and Childhood Myotonic Dystrophy Health Index: Parent Proxy Instrument

Issue date: September 09, 2014

Patent #: TXu 1-939-207

Country: United States

Inventors: Chad R Heatwole, Nicholas E Johnson

Congenital and Childhood Myotonic Dystrophy Health Index: Instrument for Children Ages 12 to 17

Issue date: September 09, 2014

Patent #: TXu 1-920-540

Country: United States

Inventors: Chad R Heatwole, Nicholas E Johnson

Congenital and Childhood Myotonic Dystrophy Health Index: Instrument for Children Ages 8 to 11

Issue date: September 09, 2014

Patent #: TXu 1-920-539

Country: United States

Inventors: Chad R Heatwole, Nicholas E Johnson

Congenital and Childhood Myotonic Dystrophy Research Survey: Instrument for Children Ages 5 to 7

Issue date: December 08, 2014

Patent #: TXu 1-933-072

Country: United States

Inventors: Chad R Heatwole, Joanna Heatwole, Nicholas E Johnson

The CMT-Health Index (CMT-HI)

Issue date: April 07, 2016

Patent #: TXu 2-181-521

Country: United States

Inventors: Chad R Heatwole, David N Herrmann, Nicholas E Johnson

Facioscapulohumeral Dystrophy Composite Outcome Measure (FSHD-COM)

Issue date: August 17, 2017

Patent #: TXu 2-056-221

Country: United States

Inventors: Katy J Eichinger, Chad R Heatwole, Jeffery Statland, Al-Rabi N Tawil

Congenital and Childhood Myotonic Dystrophy Health Index Clinician Assessment

Issue date: June 29, 2020

Patent #: TXu 2-209-015

Country: United States

Inventors: Chad R Heatwole, Nicholas E Johnson

Crohn’s Disease Health Index (CDHI)

Issue date: August 11, 2021

Patent #: TXu 2-275-092

Country: United States

Inventors: Chad R Heatwole

The Huntington Disease Health Index (HD-HI)

Issue date: November 19, 2018

Patent #: TXu 2-124-913

Country: United States

Inventors: Earl Ray Dorsey, Chad R Heatwole

The Myotonic Dystrophy Type-2 Health Index (MD2HI)

Issue date: November 19, 2018

Patent #: TXu 2-124-841

Country: United States

Inventors: Chad R Heatwole

Amyotrophic Lateral Sclerosis Health Index (ALS-HI)

Issue date: November 09, 2020

Patent #: TXu 2-227-966

Country: United States

Inventors: Chad R Heatwole

The Spinal Muscular Atrophy Health Index (SMA-HI)

Issue date: January 27, 2021

Patent #: TXu 2-244-1782

Country: United States

Inventors: Chad R Heatwole

The Friedreich's Ataxia Health Index (FA-HI)

Issue date: March 05, 2021

Patent #: TXu002242119

Country: United States

Inventors: Chad R Heatwole

The Inclusion Body Myositis Health Index (IBM-HI)

Issue date: May 11, 2021

Patent #: TXu 2-259-583

Country: United States

Inventors: Chad R Heatwole

The Duchenne Muscular Dystrophy Health Index (DMD-HI)

Issue date: May 12, 2021

Patent #: TXun2-260-028

Country: United States

Inventors: Chad R Heatwole

The Duchenne Muscular Dystrophy Caregiver Reported Health Index (DMDCR-HI)

Issue date: May 12, 2021

Patent #: TXun2-259795

Country: United States

Inventors: Chad R Heatwole

Publications

Journal Articles

The Crohn's Disease-Health Index: Development and Evaluation of a Novel Outcome Measure.

Varma A, Weinstein J, Seabury J, Rosero S, Wagner E, Zizzi C, Kaat A, Luebbe E, Dilek N, Heatwole J, Saubermann L, Temple L, Rogoff S, Heatwole C

Journal of clinical gastroenterology.. 2024 January 26 Epub 01/26/2024.

Patient Reported Impact Of Symptoms In Fibromyalgia (PRISM-FM).

Weinstein J, Rosero S, Seabury J, Varma A, Engebrecht C, Khosa S, Heatwole J, Dilek N, Kaat A, Heatwole C

The Journal of rheumatology.. 2024 January 15 Epub 01/15/2024.

A longitudinal study of disease progression in facioscapulohumeral muscular dystrophy (FSHD).

Varma A, Todinca MS, Eichinger K, Heininger S, Dilek N, Martens W, Tawil R, Statland J, Kissel JT, McDermott MP, Heatwole C

Muscle & nerve.. 2024 January 8 Epub 01/08/2024.

Friedreich's Ataxia-Health Index: Development and Validation of a Novel Disease-Specific Patient-Reported Outcome Measure.

Seabury J, Rosero S, Varma A, Weinstein J, Engebrecht C, Dilek N, Heatwole J, Alexandrou D, Cohen B, Larkindale J, Lynch DR, Park C, Subramony SH, Wagner E, Walther S, Wells M, Zizzi C, Heatwole C

Neurology. Clinical practice.. 2023 October 13 (5):e200180. Epub 08/28/2023.

The Facioscapulohumeral Muscular Dystrophy-Health Index: Development and evaluation of a disease-specific outcome measure.

Varma A, Weinstein J, Seabury J, Rosero S, Engebrecht C, Wagner E, Zizzi C, Luebbe EA, Dilek N, McDermott MP, Kissel J, Sansone V, Heatwole C

Muscle & nerve.. 2023 August 23 Epub 08/23/2023.

Patient-reported impact of symptoms in lung cancer (PRISM-LC).

Varma A, Weinstein J, Seabury J, Rosero S, Zizzi C, Dilek N, Heatwole J, Baumgart M, Mulford D, Maggiore R, Conrow L, King JC, Wiens J, Heatwole C

Translational lung cancer research.. 2023 July 3112 (7):1391-1413. Epub 07/11/2023.

Assessing Prevalence and Characteristics of Oro-bulbar Involvement in Children and Adults with SMA Type 2 and 3 Using a Multimodal Approach.

Trucco F, Salmin F, Lizio A, Coratti G, Albamonte E, Frisoni MC, Mauro L, Carraro E, Palazzo G, Lops J, Cattaneo C, Pozzi S, Casiraghi J, Di Bari A, Berti B, Stanca G, Ricci M, Pane M, Heatwole C, Dilek N, Mercuri E, Sansone VA

Dysphagia.. 2023 June 8 Epub 06/08/2023.

The facioscapulohumeral muscular dystrophy - health index: Italian validation of a disease-specific measure of symptomatic burden.

Carraro E, Greco LC, Lizio A, Beretta M, Pozzi S, Casiraghi J, Becchiati S, Beshiri F, Frisoni MC, Iossa F, Heatwole C, Sansone V

Disability and rehabilitation.. 2023 May 17 :1-8. Epub 05/17/2023.

The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure.

Varma A, Weinstein J, Seabury J, Rosero S, Zizzi C, Alexandrou D, Wagner E, Dilek N, Heatwole J, Wuu J, Caress J, Bedlack R, Granit V, Statland J, Mehta P, Benatar M, Kaat A, Heatwole C

Amyotrophic lateral sclerosis & frontotemporal degeneration.. 2023 May 15 :1-9. Epub 05/15/2023.

Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.

Thornton CA, Moxley RT, Eichinger K, Heatwole C, Mignon L, Arnold WD, Ashizawa T, Day JW, Dent G, Tanner MK, Duong T, Greene EP, Herbelin L, Johnson NE, King W, Kissel JT, Leung DG, Lott DJ, Norris DA, Pucillo EM, Schell W, Statland JM, Stinson N, Subramony SH, Xia S, Bishop KM, Bennett CF

The Lancet. Neurology.. 2023 March 22 (3):218-228. Epub 1900 01 01.

Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): A national, cross-sectional study.

Zizzi C, Seabury J, Rosero S, Alexandrou D, Wagner E, Weinstein JS, Varma A, Dilek N, Heatwole J, Wuu J, Caress J, Bedlack R, Granit V, Statland JM, Mehta P, Benatar M, Heatwole C

EClinicalMedicine.. 2023 January 55 :101768. Epub 12/13/2022.

Disease Burden in Children With Spinal Muscular Atrophy: Results From a Large Cross-Sectional Study.

Rosero S, Weinstein J, Seabury J, Zizzi C, Wagner E, Varma A, Heatwole J, Alexandrou D, Ms ND, Johnson BA, Heatwole C

Journal of child neurology.. 2022 December 19 :8830738221135918. Epub 12/19/2022.

Patient-Reported Impact of Symptoms in Friedreich Ataxia.

Seabury J, Alexandrou D, Dilek N, Cohen B, Heatwole J, Larkindale J, Lynch DR, Park C, Rosero S, Subramony SH, Varma A, Wagner E, Walther S, Weinstein J, Wells M, Zizzi C, Heatwole C

Neurology.. 2022 November 28 Epub 11/28/2022.

Patient-Reported Impact of Symptoms in Crohn's Disease.

Varma A, Weinstein J, Seabury J, Rosero S, Wagner E, Zizzi C, Luebbe E, Dilek N, McDermott M, Heatwole J, Saubermann L, Temple L, Rogoff S, Heatwole C

The American journal of gastroenterology.. 2022 November 15 Epub 11/15/2022.

Assessing Perspectives of Disease Burden and Clinically Meaningful Changes Using the Spinal Muscular Atrophy Health Index in Adolescents and Young Adults.

Mazzella A, Cruz R, Belter L, Curry M, Dilek N, Zizzi C, Heatwole C, Jarecki J

Muscle & nerve.. 2022 May 26 Epub 05/26/2022.

The Huntington's Disease Health Index: Initial Evaluation of a Disease-Specific Patient Reported Outcome Measure.

Brumfield OS, Zizzi CE, Dilek N, Alexandrou DG, Glidden AM, Rosero S, Weinstein J, Seabury J, Kaat A, McDermott MP, Dorsey ER, Heatwole CR

Journal of Huntington's disease.. 2022 May 2 Epub 05/02/2022.

Correction to: P047 The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient-Reported Outcome Measure for Clinical Trials.

Seabury J, Weinstein J, Rosero S, Varma A, Wagner E, Zizzi C, Dilek N, McDermott M, Kaat A, Saubermann L, Temple L, Rogoff S, Heatwole C

The American journal of gastroenterology.. 2022 May 1117 (5):817. Epub 03/09/2022.

Correction to: P047 The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient-Reported Outcome Measure for Clinical Trials.

Seabury J, Weinstein J, Rosero S, Varma A, Wagner E, Zizzi C, Dilek N, McDermott M, Kaat A, Saubermann L, Temple L, Rogoff S, Heatwole C

The American journal of gastroenterology.. 2022 March 9 Epub 03/09/2022.

Brief assessment of cognitive function in myotonic dystrophy: multicenter longitudinal study using computer-assisted evaluation.

Deutsch GK, Hagerman KA, Sampson J, Dent G, Dekdebrun J, Parker DM, Thornton CA, Heatwole CR, Subramony SH, Mankodi AK, Ashizawa T, Statland JM, Arnold WD, Moxley RT, Day JW,

Muscle & nerve.. 2022 February 18 Epub 02/18/2022.

P047?The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient Reported Outcome Measure for Clinical Trials.

Seabury J, Weinstein J, Rosero S, Varma A, Wagner E, Zizzi C, Dilek N, McDermott M, Kaat A, Saubermann L, Temple L, Rogoff S, Heatwole C

The American journal of gastroenterology.. 2021 December 1116 (Suppl 1):S12. Epub 1900 01 01.

P047?The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient Reported Outcome Measure for Clinical Trials.

Seabury J, Weinstein J, Rosero S, Varma A, Wagner E, Zizzi C, Dilek N, McDermott M, Kaat A, Saubermann L, Temple L, Rogoff S, Heatwole C

The American journal of gastroenterology.. 2021 December 1116 (Suppl 1):S12. Epub 1900 01 01.

Patient reported quality of life in limb girdle muscular dystrophy.

Kovalchick LV, Bates K, Statland J, Weihl C, Kang PB, Lowes LP, Mozaffar T, Straub V, Wicklund M, Heatwole C, Johnson NE

Neuromuscular disorders : NMD.. 2021 November 13 Epub 11/13/2021.

The Spinal Muscular Atrophy Health Index (SMA-HI): A Novel Outcome for Measuring How a Patient Feels and Functions.

Zizzi CE, Luebbe E, Mongiovi P, Hunter M, Dilek N, Garland C, Ciafaloni E, Zaidman CM, Kissel JT, McDermott MP, Johnson N, Sansone V, Heatwole CR

Muscle & nerve.. 2021 March 12 Epub 03/12/2021.

The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure.

Sansone VA, Pirola A, Lizio A, Greco LC, Coratti G, Casiraghi J, Pane M, Pera MC, Italiano C, Messina S, Pozzi S, Sframeli M, D'Amico A, Bertini E, Bruno C, Mauro L, Salmin F, Stancanelli C, Pedemonte M, Albamonte E, Zizzi C, Heatwole C, Mercuri E,

Neuromuscular disorders : NMD.. 2021 February 9 Epub 02/09/2021.

Mexiletine in myotonic dystrophy type-1: A randomized, double-blind, placebo-controlled trial.

Heatwole C, Luebbe E, Rosero S, Eichinger K, Martens W, Hilbert J, Dekdebrun J, Dilek N, Zizzi C, Johnson N, Puwanant A, Tawil R, Schifitto G, Beck CA, Richeson JF, Zareba W, Thornton C, McDermott MP, Moxley R

Neurology.. 2020 October 12 Epub 10/12/2020.

Minimal manifestation status and prednisone withdrawal in the MGTX trial.

Lee I, Kuo HC, Aban IB, Cutter GR, McPherson T, Kaminski HJ, Sussman J, Ströbel P, Oger J, Cea G, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJG, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Minisman G, Sonett JR, Wolfe GI,

Neurology.. 2020 July 1 Epub 07/01/2020.

Validation of the Italian version of the Charcot-Marie-Tooth Health Index (CMT-HI).

Pisciotta C, Ciafaloni E, Zuccarino R, Calabrese D, Saveri P, Fenu S, Tramacere I, Genovese F, Dilek N, Johnson NE, Heatwole C, Herrmann DN, Pareyson D,

Journal of the peripheral nervous system : JPNS.. 2020 June 8 Epub 06/08/2020.

Patient-reported impact of symptoms in Huntington disease: PRISM-HD.

Glidden AM, Luebbe EA, Elson MJ, Goldenthal SB, Snyder CW, Zizzi CE, Dorsey ER, Heatwole CR

Neurology.. 2020 May 1294 (19):e2045-e2053. Epub 03/19/2020.

Understanding the needs of people with ALS: a national survey of patients and caregivers.

Brizzi KT, Bridges JFP, Yersak J, Balas C, Thakur N, Galvin M, Hardiman O, Heatwole C, Ravits J, Simmons Z, Bruijn L, Chan J, Bedlack R, Berry JD

Amyotrophic lateral sclerosis & frontotemporal degeneration.. 2020 May 12 :1-9. Epub 05/12/2020.

Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019.

Mercuri E, Messina S, Montes J, Muntoni F, Sansone VA,

Neuromuscular disorders : NMD.. 2020 March 7 Epub 03/07/2020.

Limb-girdle muscular dystrophy: A perspective from adult patients on what matters most.

Hunter M, Heatwole C, Wicklund M, Weihl CC, Mozaffar T, Statland JM, Johnson NE

Muscle & nerve.. 2019 October 60 (4):419-424. Epub 07/24/2019.

Patient-reported disease burden in oculopharyngeal muscular dystrophy.

Kurtz NS, Cote C, Heatwole C, Gagnon C, Youssof S

Muscle & nerve.. 2019 September 18 Epub 09/18/2019.

Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD).

Hamel J, Johnson N, Tawil R, Martens WB, Dilek N, McDermott MP, Heatwole C

Neurology.. 2019 September 1793 (12):e1180-e1192. Epub 08/13/2019.

Consensus-based care recommendations for adults with myotonic dystrophy type 2.

Schoser B, Montagnese F, Bassez G, Fossati B, Gamez J, Heatwole C, Hilbert J, Kornblum C, Kostera-Pruszczyk A, Krahe R, Lusakowska A, Meola G, Moxley R, Thornton C, Udd B, Formaker P,

Neurology. Clinical practice.. 2019 August 9 (4):343-353. Epub 1900 01 01.

Patient-reported study of the impact of pediatric-onset myotonic dystrophy.

Hunter M, Ekstrom AB, Campbell C, Hung M, Bounsanga J, Bates K, Adams HR, Luebbe E, Moxley RT, Heatwole C, Johnson NE

Muscle & nerve.. 2019 July 12 Epub 07/12/2019.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A, Newsom-Davis J, Cutter GR,

The Lancet. Neurology.. 2019 March 18 (3):259-268. Epub 01/25/2019.

The myotonic dystrophy health index: Japanese adaption and validity testing.

Mori I, Fujino H, Matsumura T, Takada H, Ogata K, Nakamori M, Innami K, Shingaki H, Imura O, Takahashi MP, Heatwole C

Muscle & nerve.. 2019 January 25 Epub 01/25/2019.

The myotonic dystrophy experience: a North American cross-sectional study.

Hagerman KA, Howe SJ, Heatwole CR,

Muscle & nerve.. 2019 January 24 Epub 01/24/2019.

Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 2.

Benedikt Schoser; Federica Montagnese; Guillaume Bassez; Barbara Fossati; Josep Gamez; Chad Heatwole; James Hilbert; Cornelia Kornblum; Anne Kostera-Pruszczyk; Ralf Krahe; Anna Lusakowska; Giovanni Meola; Richard Moxley; Charles Thornton; Bjarne Udd; Paul Formaker.

Neurology: Clinical Practice. [In print]. 2019; .

Limb?Girdle Muscular Dystrophy: A perspective from adult patients on what matters most.

Hunter M, Heatwole C, Wicklund M, Weihl CC, Mozaffar T, Statland JM, Johnson NE.

Muscle & Nerve. 2019; .

Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD).

Johanna Hamel, Nicholas E. Johnson, Rabi Tawil, William B. Martens, Nuran Dilek, Michael P. McDermott, and Chad Rydel Heatwole.

Neurology. 2019; .

Consensus-based care recommendations for adults with myotonic dystrophy type 1.

Ashizawa T, Gagnon C, Groh WJ, Gutmann L, Johnson NE, Meola G, Moxley R, Pandya S, Rogers MT, Simpson E, Angeard N, Bassez G, Berggren KN, Bhakta D, Bozzali M, Broderick A, Byrne JLB, Campbell C, Cup E, Day JW, De Mattia E, Duboc D, Duong T, Eichinger K, Ekstrom AB, van Engelen B, Esparis B, Eymard B, Ferschl M, Gadalla SM, Gallais B, Goodglick T, Heatwole C, Hilbert J, Holland V, Kierkegaard M, Koopman WJ, Lane K, Maas D, Mankodi A, Mathews KD, Monckton DG, Moser D, Nazarian S, Nguyen L, Nopoulos P, Petty R, Phetteplace J, Puymirat J, Raman S, Richer L, Roma E, Sampson J, Sansone V, Schoser B, Sterling L, Statland J, Subramony SH, Tian C, Trujillo C, Tomaselli G, Turner C, Venance S, Verma A, White M, Winblad S

Neurology. Clinical practice.. 2018 December 8 (6):507-520. Epub 1900 01 01.

The relationship between deficit in digit span and genotype in nonsense mutation Duchenne muscular dystrophy.

Thangarajh M, Elfring GL, Trifillis P, McIntosh J, Peltz SW,

Neurology.. 2018 September 2591 (13):e1215-e1219. Epub 08/22/2018.

Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA).

Mongiovi P, Dilek N, Garland C, Hunter M, Kissel JT, Luebbe E, McDermott MP, Johnson N, Heatwole C

Neurology.. 2018 September 2591 (13):e1206-e1214. Epub 08/24/2018.

Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1-year follow-up study.

Mul K, Heatwole C, Eichinger K, Dilek N, Martens WB, van Engelen BGM, Tawil R, Statland JM

Muscle & nerve.. 2018 August 58 (2):213-218. Epub 04/17/2018.

The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.

Johnson NE, Heatwole C, Creigh P, McDermott MP, Dilek N, Hung M, Bounsanga J, Tang W, Shy ME, Herrmann DN

Annals of neurology.. 2018 August 84 (2):225-233. Epub 08/29/2018.

222nd ENMC International Workshop:: Myotonic dystrophy, developing a European consortium for care and therapy, Naarden, The Netherlands, 1-2 July 2016.

Wood L, Bassez G, van Engelen B, Lochmüller H, Schoser B,

Neuromuscular disorders : NMD.. 2018 May 28 (5):463-469. Epub 02/12/2018.

French translation and cross-cultural adaptation of The Myotonic Dystrophy Health Index.

Gagnon C, Tremblay M, Côté I, Heatwole C

Muscle & nerve.. 2018 April 57 (4):686-689. Epub 11/14/2017.

Facioscapulohumeral muscular dystrophy functional composite outcome measure.

Eichinger K, Heatwole C, Iyadurai S, King W, Baker L, Heininger S, Bartlett A, Dilek N, Martens WB, McDermott M, Kissel JT, Tawil R, Statland JM

Muscle & nerve.. 2018 January 30 Epub 01/30/2018.

Myotonic dystrophy patient preferences in patient-reported outcome measures.

Heatwole C, Johnson N, Dekdebrun J, Dilek N, Eichinger K, Hilbert J, Luebbe E, Martens W, McDermott MP, Thornton C, Moxley R

Muscle & nerve.. 2018 January 12 Epub 01/12/2018.

Patient-identified impact of symptoms in spinal and bulbar muscular atrophy.

Guber RD, Kokkinis AD, Schindler AB, Bendixen RM, Heatwole CR, Fischbeck KH, Grunseich C

Muscle & nerve.. 2018 January 57 (1):40-44. Epub 09/25/2017.

A Qualitative Approach to Health Related Quality-of-Life in Congenital Muscular Dystrophy.

Cornwall KM, Butterfield RJ, Hernandez A, Heatwole C, Johnson NE

Journal of neuromuscular diseases.. 2018 5 (2):251-255. Epub 1900 01 01.

Report of the third outcome measures in myotonic dystrophy type 1 (OMMYD-3) international workshop Paris, France, June 8, 2015.

Gagnon C, Heatwole C, Hébert LJ, Hogrel JY, Laberge L, Leone M, Meola G, Richer L, Sansone V, Kierkegaard M

Journal of neuromuscular diseases.. 2018 5 (4):523-537. Epub 1900 01 01.

The Myotonic Dystrophy Health Index: Italian validation of a disease-specific outcome measure.

Sansone VA, Lizio A, Greco L, Gragnano G, Zanolini A, Gualandris M, Iatomasi M, Heatwole C

Neuromuscular disorders : NMD.. 2017 November 27 (11):1047-1053. Epub 07/10/2017.

225th ENMC international workshop:: A global FSHD registry framework, 18-20 November 2016, Heemskerk, The Netherlands.

Mul K, Kinoshita J, Dawkins H, van Engelen B, Tupler R,

Neuromuscular disorders : NMD.. 2017 August 27 (8):782-790. Epub 04/12/2017.

Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation-Sponsored Workshop.

Hesterlee S, Amur S, Bain LJ, Carulli J, Clarke S, Day JW, Gagnon C, Hagerman K, Heatwole C, Johnson NE, Moxley R, Patel N, Thornton C, Kessel W, White M

Therapeutic innovation & regulatory science.. 2017 July 51 (4):516-522. Epub 02/09/2017.

Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.

Eichinger K, Heatwole C, Heininger S, Stinson N, Matichak Stock C, Grosmann C, Wagner KR, Tawil R, Statland JM,

Muscle & nerve.. 2017 March 55 (3):333-337. Epub 12/05/2016.

Prospective Measurement of Quality of Life in Myotonic Dystrophy Type 1.

Peric S; Heatwole, C; Durovic, E; Kacar, A; Nikolic, A; Basta, I; Marjanovic, A; Stevic, Z; Lavrnic, D; Stojanovic, V.

Acta Neurologica Scandinavica. 2017; 136(6): 694-697.

Inclusion Body Myositis: What Most Impacts Patients' Lives.

Gibson C, Johnson NE, Eastwood E, Heatwole C

Journal of clinical neuromuscular disease.. 2016 December 18 (2):67-71. Epub 1900 01 01.

Electrical impedance myography in facioscapulohumeral muscular dystrophy.

Statland JM, Heatwole C, Eichinger K, Dilek N, Martens WB, Tawil R

Muscle & nerve.. 2016 October 54 (4):696-701. Epub 05/25/2016.

What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients.

Hunter M, Heatwole C, Luebbe E, Johnson NE

Journal of neuromuscular diseases.. 2016 August 303 (3):425-429. Epub 1900 01 01.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A, Newsom-Davis J, Cutter GR,

The New England journal of medicine.. 2016 August 11375 (6):511-22. Epub 1900 01 01.

Disease burden and functional outcomes in congenital myotonic dystrophy: A cross-sectional study.

Johnson NE, Butterfield R, Berggren K, Hung M, Chen W, DiBella D, Dixon M, Hayes H, Pucillo E, Bounsanga J, Heatwole C, Campbell C

Neurology.. 2016 July 1287 (2):160-7. Epub 06/15/2016.

Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy.

Johnson NE, Ekstrom AB, Campbell C, Hung M, Adams HR, Chen W, Luebbe E, Hilbert J, Moxley RT, Heatwole CR

Developmental medicine and child neurology.. 2016 July 58 (7):698-705. Epub 10/28/2015.

Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Heatwole C, Bode R, Nicholas Johnson , Dekdebrun J, Dilek N, Eichinger K, Hilbert JE, Logigian E, Luebbe E, Martens W, McDermott MP, Pandya S, Puwanant A, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT

Muscle & nerve.. 2016 February 53 (2):183-90. Epub 12/29/2015.

Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).

Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, Luebbe E, Martens W, McDermott MP, Quinn C, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT

Neurology.. 2015 December 1585 (24):2136-46. Epub 11/18/2015.

The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study.

Johnson NE, Hung M, Nasser E, Hagerman KA, Chen W, Ciafaloni E, Heatwole CR

Journal of neuromuscular diseases.. 2015 October 72 (4):447-452. Epub 1900 01 01.

Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients.

Johnson NE, Arnold WD, Hebert D, Gwathmey K, Dimachkie MM, Barohn RJ, McVey AL, Pasnoor M, Amato AA, McDermott MP, Kissel J, Heatwole CR

Neuromuscular disorders : NMD.. 2015 August 25 (8):625-31. Epub 05/07/2015.

Report of the second Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-2) international workshop San Sebastian, Spain, October 16, 2013.

Gagnon C, Meola G, Hébert LJ, Laberge L, Leone M, Heatwole C

Neuromuscular disorders : NMD.. 2015 July 25 (7):603-16. Epub 01/27/2015.

Measuring quality of life in muscular dystrophy.

Bann CM, Abresch RT, Biesecker B, Conway KC, Heatwole C, Peay H, Scal P, Strober J, Uzark K, Wolff J, Margolis M, Blackwell A, Street N, Montesanti A, Bolen J

Neurology.. 2015 March 1084 (10):1034-42. Epub 02/06/2015.

Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective.

Johnson NE, Heatwole CR, Dilek N, Sowden J, Kirk CA, Shereff D, Shy ME, Herrmann DN,

Neuromuscular disorders : NMD.. 2014 November 24 (11):1018-23. Epub 06/27/2014.

Ataluren treatment of patients with nonsense mutation dystrophinopathy.

Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Lee Sweeney H, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O'donnell MW, Peltz SW, Mcdonald CM,

Muscle & nerve.. 2014 October 50 (4):477-87. Epub 1900 01 01.

The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms.

Johnson NE, Luebbe E, Eastwood E, Chin N, Moxley RT, Heatwole CR

Journal of child neurology.. 2014 July 29 (7):983-6. Epub 04/22/2013.

Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.

Heatwole C, Bode R, Johnson N, Dekdebrun J, Dilek N, Heatwole M, Hilbert JE, Luebbe E, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley R

Muscle & nerve.. 2014 June 49 (6):906-14. Epub 1900 01 01.

Splicing biomarkers of disease severity in myotonic dystrophy.

Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson M, Moxley RT, Thornton CA

Annals of neurology.. 2013 December 74 (6):862-72. Epub 1900 01 01.

Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.

Johnson NE, Heatwole CR, Ferguson M, Sowden JE, Jeanat S, Herrmann DN

Journal of clinical neuromuscular disease.. 2013 September 15 (1):19-23. Epub 1900 01 01.

Teaching video neuroimages: trapezius myotonia percussion sign in myotonic dystrophy type 2.

Johnson NE, Heatwole CR

Neurology.. 2013 June 1180 (24):e251. Epub 1900 01 01.

The diagnosis and treatment of myotonic disorders.

Heatwole CR, Statland JM, Logigian EL

Muscle & nerve.. 2013 May 47 (5):632-48. Epub 03/27/2013.

Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy.

Statland JM, McDermott MP, Heatwole C, Martens WB, Pandya S, van der Kooi EL, Kissel JT, Wagner KR, Tawil R

Neuromuscular disorders : NMD.. 2013 April 23 (4):306-12. Epub 02/11/2013.

Consensus on Cerebral Involvement in Myotonic Dystrophy Workshop Report

Heatwole, C.

Neuromuscular Disorders. 2013; In press.

Patient-identified disease burden in facioscapulohumeral muscular dystrophy.

Johnson NE, Quinn C, Eastwood E, Tawil R, Heatwole CR

Muscle & nerve.. 2012 December 46 (6):951-3. Epub 1900 01 01.

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).

Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Moxley R

Neurology.. 2012 July 2479 (4):348-57. Epub 07/11/2012.

Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.

Heatwole C, Johnson N, Holloway R, Noyes K

Journal of clinical neuromuscular disease.. 2011 December 13 (2):85-94. Epub 1900 01 01.

Laboratory abnormalities in patients with myotonic dystrophy type 2.

Heatwole C, Johnson N, Goldberg B, Martens W, Moxley R

Archives of neurology.. 2011 September 68 (9):1180-4. Epub 1900 01 01.

Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.

Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, Martens WB, McDermott MP, Pandya SK, Quinn C, Smirnow AM, Thornton CA, Moxley RT

Archives of neurology.. 2011 January 68 (1):37-44. Epub 09/13/2010.

Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1.

Logigian EL, Twydell P, Dilek N, Martens WB, Quinn C, Wiegner AW, Heatwole CR, Thornton CA, Moxley RT

Muscle & nerve.. 2010 February 41 (2):191-6. Epub 1900 01 01.

Mycophenolate mofetil for myasthenia gravis: a clear and present controversy.

Heatwole C, Ciafaloni E

Neuropsychiatric disease and treatment.. 2008 December 4 (6):1203-9. Epub 1900 01 01.

International Education Issues: practicing and teaching international neurology: the Krakow experience.

Heatwole C

Neurology.. 2007 October 2369 (17):1721-3. Epub 1900 01 01.

The nondystrophic myotonias.

Heatwole CR, Moxley RT

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.. 2007 April 4 (2):238-51. Epub 1900 01 01.

Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1.

Heatwole CR, Miller J, Martens B, Moxley RT

Archives of neurology.. 2006 August 63 (8):1149-53. Epub 1900 01 01.

Extreme spindles: a distinctive EEG pattern in Mycoplasma pneumoniae encephalitis.

Heatwole CR, Berg MJ, Henry JC, Hallman JL

Neurology.. 2005 March 2264 (6):1096-7. Epub 1900 01 01.

Books

Swaiman's Pediatric Neurology Principles and Practice Sixth Edition (2017)

Chapter: Channelopathies: Myotonic Disorders and Periodic Paralysis

Authors: Heatwole, C; Moxley, R.

Publisher: Elsevier 2017

AANEM (2014)

Chapter: Myotonic Dystrophy Health Index: Initial Evaluation of a Disease-Specific Outcome Measure

Authors: Heatwole, C

Publisher: AANEM podcast 2014

Swaiman's Pediatric Principles and Practice 5th edition (2012)

Chapter: Channelopathies: Myotonic Disorders and Periodic Paralysis

Authors: Heatwole, C; Moxley, R.

Publisher: Elsevier Saunders 2012

Neuromuscular Disorders (2011)

Chapter: Myotonic Dystrophies

Authors: Johnson, N; Heatwole, C

Publisher: Blackwell Publishing Ltd 2011

The Corridor (2009)

Authors: C.R. Heatwole

Publisher: James A Rock & Co. Publishers 2009

Principles of Drug Therapy in Neurology (2008)

Chapter: Pharmacologic Treatment of Neuromuscular Disease

Authors: Chad R. Heatwole, MD; Richard T. Moxley III, MD

Publisher: F.A. Davis 2008

Minimizing the Spread of Infectious Disease Through Lavatory Design. (2007)

Authors: Heatwole, CR; Heatwole, CM; Heatwole, EE; Potts, EE

Publisher: Engineering Design and Construction 2007

Land of Beauty and Hardship: SET in Nepal (2005)

Authors: Heatwole, CR.

Publisher: The Mennonite Health Journal. 7:3 2005

SET Training in the Land of Mt. Everest. (2002)

Authors: Heatwole, CR.

Publisher: The Mennonite Health Journal 4:1 2002

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.